Drug Updates

Update on Taliglucerase alfa for injection (Elelyso™ Differin®) as well as devices like Nd:YAG surgical laser (Fotona® XP Laser), Q-switched laser for melasma (Spectra™), Diode hair removal laser (Advantage™), Low-level laser diode device for circumferential reduction (i-Lipo™), Multiwavelength diode laser (Evolve® HPD)

Update on drugs, approval dates, and comments. Belimumab Adapalene (0.3% gel Differin®), Vemurafenib tablet (Zelboraf®), Wound care spray (Granulox®), as well as devices like the laser device for onychomycosis Harmony® XL are covered.

Update on drugs, approval dates, and comments. Ivermectin 0.5% lotion (Sklice™), Ipilimumab (Yervoy™), Vemurafenib (Zelboraf®), are covered, as well as the Cellulite removal laser device Cellulaze™ Cellulite Laser Workstation.

Update on drugs, approval dates, and comments. Ingenol mebutate gel (0.015%, 0.05%) Picato® and Vismodegib capsule (Erivedge™) are covered.

Update on drugs, approval dates, and comments. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Hyaluronic acid-based dermal filler (Belotero® Balance), Drospirenone 3 mg + ethinyl estradiol 0.02 mg (Vestura™) are covered.

Update on drugs, approval dates, and comments. Dimethicone 50% topical solution (Nyda®), Radiofrequency aesthetic device (EXILIS Focused RF™), Skin barrier protectant (Neosalus® Lotion) are covered.

Update on drugs, approval dates, and comments. Belimumab (Benlysta™), Tolnaftate 1% Cream (Tolnaftate-D™), Hydrocortisone 1% Cream (Hydrocortisone-D™), Ketoconazole 2% Foam are covered.

Update on drugs, approval dates, and comments. IncobotulinumtoxinA injection (Xeomin®), Vemurafenib tablets (Zelboraf™ cobas®), Icatibant injection (Firazyr®) are covered.

Update on Autologous cell therapy dermal filler [laVív® (azficel-T)], 5-fluorouracil cream 0.5% + Salicylic acid 10% (Actikerall®), Belimumab (Benlysta®), Ipilimumab (Yervoy™).

Update on drugs, approval dates, and comments. Human papillomavirus (HPV) test (Cobas® HPV Test Cobas® 4800 System), Betamethasone valerate 0.12% foam (Luxiq®) are covered.

Update on Peginterferon alfa-2b (Sylatron™), Imiquimod 3.75% cream (Zyclara®), experienced recurrence 12 weeks after therapy. (Adapalene 0.1% + benzoyl peroxide 2.5% gel Tactuo™), Collagenase clostridium histolyticum (Xiapex®), and updates on generic drugs.

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Ipilimumab (Yervoy™), Imiquimod 3.75% Cream (Vyloma™) are covered.

Update on drugs, approval dates, and comments. Gabapentin tablets GRALISE™(DM-1796), Oxychlorine compound (Epicyn™ HydroGel), Collagenase clostridium histolyticum (XIAPEX®) as well as drug news on HPV vaccines.

Update on drugs, approval dates, and comments. Spinosad 0.9% cream rinse (Natroba™), Light emitting diode (LED) skin rejuvenation system (Tanda™ Professional Rejuvenate), Voclosporin Voclera™ (ISA247) are covered.

Update on drugs, approval dates, and comments. Human papillomavirus quadrivalent (Types 6, 11, 16, and 18) recombinant vaccine (Gardasil®), Daptomycin for injection (Cubicin®) are covered.

Update on drugs, approval dates, and comments. Calcipotriene/Calcipotriol0.005% foam (Sorilux™), Ceftaroline fosamil (Teflaro™) are covered as well as an update on Health Canada on the use of tacrolimus (Protopic®) for atopic dermatitis.

Update on drugs, approval dates, and comments. Drospirenone /ethinyl estradiol /levomefolate calcium + levomefolate calcium tablets (Beyaz™), Imiquimod 5% cream are covered.

October 2010: Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®), and recent news with Health Canada.

Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®) and Health Canada labelling changes for isopropyl myristate 50% rinse (Resultz®, Nycomed) to include the treatment of lice in children =2 years of age are covered.

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Adapalene 0.1% gel, Antiseborrheic compound (K301/Kaprolac®) are covered.

Update on CD56-binding monoclonal antibody (huN901) + maytansinoid cytotoxic agent (DM1) IMGN901, Small molecule oxychlorine compound (Microcyn® Skin and Wound HydroGel), Antifungal agent (K101/Kaprolac®).

Update on drugs, approval dates, and comments. Imiquimod 3.75% cream (Zyclara™), Adapalene 0.1% lotion (Differin®), Polidocanol injection (Asclera®) are covered.

Update on drugs, approval dates, and comments. Collagenase clostridium histolyticum (XIAFLEX™), HPV quadrivalent recombinant vaccine (Gardasil®), Velaglucerase alfa (VPRIV™), Agalsidase alfa (REPLAGAL®), Adalimumab (Humira®) are covered.

Update on Hyaluronic acid dermal filler + 0.3% lidocaine JUVÉDERM® XC, Hyaluronic acid dermal filler + 0.3% lidocaine RESTYLANE®-L PERLANE®-L, and news on labeling changes regarding possible hepatic effects of diclofenac sodium topical gel 1% (Voltaren® Gel).

Update on Imiquimod 3.75% Cream Zyclara™, Acyclovir + Hydrocortisone Cream Xerclear®/Lipsovir®, as well as drug news on Titanium dioxide (TiO2).

Update on Capsaicin 8% Patch Qutenza™, Alitretinoin Capsule Toctino® as well as news about a recent study by Kenter et al.* explored the efficacy of a human papillomavirus (HPV) vaccine.

Updates on Ustekinumab Stelara® Centocor Ortho Biotech, Romidepsin ISTODAX® Gloucester Pharmaceuticals and news from US FDA.

Update on Collagen-based dermal filler Evolence®, Injectable Poly-L-lactic acid Sculptra Aesthetic®, Ibritumomab tiuxetan Zevalin®, and news from US FDA on TNF blockers.

Update on Benzyl Alcohol Lotion 5% Sciele Pharma, Red Light Technology Device + Methyl Aminolevulinate Cream Aktilite® CL 128 + Metvix®, and news Nexavar®.

Update on Golimumab (Simponi™) Centocor/Schering-Plough, Darunavir (PREZISTA™) Tibotec/Janssen-Ortho, Telavancin (Arbelic™) Theravance/Astellas, and news from US FDA.

Update on Alitretinion (Toctino®), Pralatrexate, Benzyl Alcohol Lotion 5%, and Botulinum Toxin – Type A (Azzalure®) and news on Efalizumab (Raptiva®).

Update on Ustekinumab Stelara®, Photopheresis System THERAKOS™ CELLEX™, Calcitriol Vectical™ Ointment, Autologous Collagen Cellular Processing System Isolagen Therapy™.

Update on Alitretinoin (Toctino®), Denileukin Diftitox (Ontak™), Bimatoprost Ophthalmic 0.03% Solution (LATISSE®), Maraviroc (SELZENTRY®), Clindamycin Phosphate 1.2% + Benzoyl Peroxide 2.5% (Acanya® Gel), Etanercept (Enbrel®).

Update on Ceftobiprole (Zeftera®) Johnson & Johnson/ Basilea Pharmaceuticals, IV Iclaprim Arpida Ltd., HPV Vaccine (Gardasil®) Merck & Co., Alitretinoin (Toctino®) Basilea Pharmaceuticals, and Atazanavir sulfate (REYATAZ®) Bristol-Myers Squibb.

Update on Bimatoprost Ophthalmic Solution 0.03% Lumigan®, Ustekinumab (CNTO-1275) Centocor, p53 tumor suppressor therapy ADVEXIN®, Shingles Vaccine Zostavax®, Calcipotriene 0.005% + betamethasone dipropionate 0.064% Xamiol® Gel, and Etanercept Enbrel®.

Update on Certolizumab pegol Cimzia® UCB S.A., Golimumab Centocor, Ceftobiprole medocaril ZEFTERA® Basilea Pharmaceuticals, and Tipranavir Aptivus® Boehringer-Ingelheim.

Update on Adapalene Differin® Gel 0.1%, Methyl Aminolevulinate Hydrochloride Cream Metvixia™ + Aktilite®, and Cross-linked Collagen EVOLENCE®.

Update on Calcipotriene 0.005% + Betamethasone Dipropionate 0.064% Topical Suspension (Taclonex Scalp®), Calcipotriene 0.005% Topical Solution, and Botulinum Toxin Type A (Reloxin®) and news about new drugs for acne and psoriasis.

Update on Triphendiol (formerly NV-196), Cyclic pentapeptide vascular-targeting agent ADH-1, Certolizumab pegol Cimzia® and drug news from around the world.

Update on Peginterferon alfa-2b PEG-Intron™, Elesclomol (formerly STA-4783), Hyaluronic Acid Gel + Lidocaine Prevelle Silk™.